FTSE Russell Silence Therapeutics (6423T)
25 November 2021 - 6:30PM
UK Regulatory
TIDMSLN TIDMSQZ TIDMPANR
RNS Number : 6423T
FTSE Russell
25 November 2021
Silence Therapeutics (UK): Constituent Deletion
Changes in FTSE UK Index Series
25 November 2021
Subject to the expected cancellation of trading on AIM for Silence Therapeutics (UK, constituent),
please see details of affected indexes and effective dates below:
Index Effective From
Start of Trading
FTSE AIM UK 50 Index 30 November 2021
FTSE AIM 100 Index 30 November 2021
------------------
FTSE AIM All-Share Index 30 November 2021
------------------
For further information please contact FTSE Russell Client Services at info@ftserussell.com
or call: Australia +1800 653 680
Hong Kong +852 2164 3333
Japan +81 3 4563 6346
London +44 (0) 20 7866 1810
New York +1866 551 0617
Alternatively please visit our website at www.ftserussell.com
Terms of Use | Copyright (c) 2021 FTSE Russell
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FTSDKPBDPBDDCDB
(END) Dow Jones Newswires
November 25, 2021 12:30 ET (17:30 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Silence Therapeutics Plc (Londoner Börse): 0 Nachrichtenartikel
Weitere Silence Therapeutics Plc News-Artikel